A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Multiple Oral Doses of BAY1834845 in Healthy Male Subjects and in Female and Male Patients With Psoriasis Over an Extended Treatment Duration
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs BAY 1834845 (Primary) ; Midazolam
- Indications Plaque psoriasis; Psoriasis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 11 Nov 2019 Planned number of patients changed from 88 to 78.
- 18 Mar 2019 Planned End Date changed from 23 Mar 2020 to 3 Aug 2020.
- 18 Nov 2018 Planned End Date changed from 23 Aug 2019 to 23 Mar 2020.